Duration of antipsychotic drug therapy in real-world practice: A comparison with CATIE trial results

Value in Health

Volumn 11, Issue 3, 2008, Pages 487-496

  Chen, Lei ^a,b   McCombs, Jeffrey S ^a   Park, Jinhee ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ANALYSIS GROUP   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Antipsychotic drugs; Duration of therapy; Switching

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TREATMENT DURATION;

EID: 44049100370     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00262.x     Document Type: Article

References (18)

1. TW Croghan BM Johnstone DP Buesching RC Kessler Information needs for medication coverage decisions in a state Medicaid program Med Care 37 Suppl. 1999 S24 S31
2. JA Lieberman TS Stroup JP McEvoy Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 2005 1209 1223
3. TS Stroup JA Lieberman JP McEvoy Effectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic Am J Psychiatry 163 2006 611 622
4. JP McEvoy JA Liberman TS Stroup Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment Am J Psychiatry 163 2006 600 610
5. RA Rosenheck DL Leslie J Sindelar Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia Am J Psychiatry 163 2006 2080 2089
6. SM Essock NH Covell SM Davis Effectiveness of switching antipsychotic medications Am J Psychiatry 163 2006 2090 2095
7. KL Rascati MT Johnsrud ML Crismon Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaik patients Pharmacoeconomics 21 2003 683 697
8. PJ Gibson R Damler EA Jackson The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population Value Health 7 2004 22 35
9. Ramsey JL, Hutchins D, Zhu B, et al. Characteristics and treatment costs of olanzapine, risperidone or haloperidol in a state Medicaid program. Poster Presented at the Annual Meetings for the Institute on Psychiatric Services, 2002.
10. Zhao Z, Damler RM, Jackson EA, Ramsey J. Atypical antipsychotic treatment adherence and persistence in a state Medicaid program. Poster Presented at the Annual Meetings of the International. Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 2004.
11. Swartz M, Zhu B, Ascher-Svanum H, et al. Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. Poster presented at the International Congress on Schizophrenia Research, Savannah, GA, April 2005.
12. Haro JM Novik D, Belger S, et al. Antipsychotic treatment discontinuation in the outpatient treatment for schizophrenia. 24-month results from the Pan-European SOHO (Schizophrenia Outpatient Health Outcomes) study. Poster presented at the International Congress on Schizophrenia Research, Savannah, GA, April 2005.
13. PW Choo CS Rand TA Inui Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence in antihypertensive therapy Med Care 32 1999 1152 1157
14. R Grymonpre M Cheang M Fraser Validity of a prescription claims database to estimate medication adherence in older people Med Care 44 2006 471 477
15. PJ Weiden C Kozma A Grogg J Locklear Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia Psychiatr Serv 55 2004 886 891
16. JS McCombs P Mulani JP Gibson Open access to innovative drugs: treatment substitutions or treatment expansion? Health Care Financ Rev 35 2004 35 53
17. H White A heteroscedasticity-consistent matrix estimator and a direct test for heteroscedasticity Econometrica 48 1980 817 838
18. StataCorp STATA 8.2 2004 StataCorp College Station, TX